Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7119 first-in-human dose-escalation and expansion study alone and with ONO-4538 in advanced solid tumors
jRCT2031210373Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of atamparib and nivolumab in Nonhematologic neoplasms (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Safety and tolerability. Started Nov 2021; status: completed.
02
Drugs
atamparibnivolumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031210373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210373.